Survodutide

Boehringer's obesity drug shows efficacy, faces tolerability challenge

In a pivotal Phase 3 obesity trial, 19% of patients on Boehringer Ingelheim and Zealand Pharma's experimental drug survodutide discontinued treatment due to severe gastrointestinal side effects, a rat